JP2024515344A5 - - Google Patents
Info
- Publication number
- JP2024515344A5 JP2024515344A5 JP2023564255A JP2023564255A JP2024515344A5 JP 2024515344 A5 JP2024515344 A5 JP 2024515344A5 JP 2023564255 A JP2023564255 A JP 2023564255A JP 2023564255 A JP2023564255 A JP 2023564255A JP 2024515344 A5 JP2024515344 A5 JP 2024515344A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- item
- composition according
- pharmaceutically acceptable
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025066627A JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177254P | 2021-04-20 | 2021-04-20 | |
| US63/177,254 | 2021-04-20 | ||
| PCT/US2022/025648 WO2022226127A1 (en) | 2021-04-20 | 2022-04-20 | Compositions and methods for inhibiting complement component 3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066627A Division JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515344A JP2024515344A (ja) | 2024-04-09 |
| JP2024515344A5 true JP2024515344A5 (enExample) | 2025-04-23 |
Family
ID=83723122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564255A Pending JP2024515344A (ja) | 2021-04-20 | 2022-04-20 | 補体成分３の発現を阻害するための組成物及び方法 |
| JP2025066627A Pending JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066627A Pending JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250002908A1 (enExample) |
| EP (1) | EP4326876A4 (enExample) |
| JP (2) | JP2024515344A (enExample) |
| KR (1) | KR20230173116A (enExample) |
| CN (1) | CN117295819A (enExample) |
| AU (1) | AU2022261922A1 (enExample) |
| BR (1) | BR112023021703A2 (enExample) |
| CA (1) | CA3177629A1 (enExample) |
| CO (1) | CO2023014681A2 (enExample) |
| IL (1) | IL307721A (enExample) |
| MX (1) | MX2023012385A (enExample) |
| WO (1) | WO2022226127A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| WO2024169907A1 (zh) * | 2023-02-17 | 2024-08-22 | 苏州时安生物技术有限公司 | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 |
| CN121488036A (zh) * | 2023-07-21 | 2026-02-06 | 上海舶望制药有限公司 | 用于抑制补体成分3(c3)表达的组合物和方法 |
| WO2025168134A1 (zh) * | 2024-02-08 | 2025-08-14 | 北京安龙生物医药有限公司 | 靶向补体成分c3基因的寡核苷酸及其用途 |
| CN121154665B (zh) * | 2025-11-21 | 2026-02-27 | 天津医科大学第二医院 | 尿苷在防治糖尿病肾病药物开发过程中及药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| CA2670801A1 (en) * | 2005-11-30 | 2007-06-07 | Intradigm Corporation | Compositions and methods of using sirna to knockdown gene expression and to improve solid organ and cell transplantation |
| WO2010042755A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
| SG10201804960RA (en) * | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| RU2019113301A (ru) * | 2016-10-17 | 2020-11-17 | Апеллис Фармасьютикалс, Инк. | Комбинированная терапия для ингибирования с3 |
| SG11202002940QA (en) * | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
| US20220017899A1 (en) * | 2018-11-23 | 2022-01-20 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| BR112022003513A2 (pt) * | 2019-08-27 | 2022-05-17 | Silence Therapeutics Gmbh | Ácidos nucleicos para inibição da expressão de c3 em uma célula |
| WO2021081026A1 (en) * | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| IL295517A (en) * | 2020-02-14 | 2022-10-01 | Apellis Pharmaceuticals Inc | Rnas for complement inhibition |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| EP4346844A4 (en) * | 2021-05-26 | 2025-09-10 | Apellis Pharmaceuticals Inc | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS |
-
2022
- 2022-04-20 WO PCT/US2022/025648 patent/WO2022226127A1/en not_active Ceased
- 2022-04-20 CN CN202280034163.4A patent/CN117295819A/zh active Pending
- 2022-04-20 CA CA3177629A patent/CA3177629A1/en active Pending
- 2022-04-20 JP JP2023564255A patent/JP2024515344A/ja active Pending
- 2022-04-20 BR BR112023021703A patent/BR112023021703A2/pt unknown
- 2022-04-20 IL IL307721A patent/IL307721A/en unknown
- 2022-04-20 EP EP22792454.5A patent/EP4326876A4/en active Pending
- 2022-04-20 US US18/287,260 patent/US20250002908A1/en active Pending
- 2022-04-20 KR KR1020237036421A patent/KR20230173116A/ko active Pending
- 2022-04-20 AU AU2022261922A patent/AU2022261922A1/en active Pending
- 2022-04-20 MX MX2023012385A patent/MX2023012385A/es unknown
-
2023
- 2023-10-30 CO CONC2023/0014681A patent/CO2023014681A2/es unknown
-
2025
- 2025-04-15 JP JP2025066627A patent/JP2025100729A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515344A5 (enExample) | ||
| JP2025160304A5 (enExample) | ||
| JP2024037871A5 (enExample) | ||
| JP2023523790A5 (enExample) | ||
| JP2024541989A5 (enExample) | ||
| JP2025503034A5 (enExample) | ||
| JP2023530461A5 (enExample) | ||
| JP2019214587A5 (enExample) | ||
| IL277970B2 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease | |
| TW201726918A (zh) | 抑制lpa之基因表現之組合物及方法 | |
| CN113795280A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| JP2017500031A5 (enExample) | ||
| JP2023506258A5 (enExample) | ||
| JP2020529197A5 (enExample) | ||
| WO2019189591A1 (ja) | 一本鎖ｒｎａの製造方法 | |
| CN121079412A (zh) | 经修饰的指导rna | |
| JP2025100729A (ja) | 補体成分３の発現を阻害するための組成物及び方法 | |
| TW202340463A (zh) | 調節補體因子b之組合物及其使用方法 | |
| WO2021110148A1 (zh) | siRNA缀合物、双链siRNA缀合物及其盐和应用 | |
| CN115927337A (zh) | 一种siRNA及其缀合物 | |
| TW202313068A (zh) | 用於抑制黏蛋白５ＡＣ（ＭＵＣ５ＡＣ）表現之ＲＮＡｉ藥劑、其組合物及使用方法 | |
| WO2025252255A1 (zh) | 抑制FXI基因表达的siRNA、其缀合物和药物组合物及用途 | |
| WO2025067351A2 (en) | Novel sirna constructs, therapeutics, and modifications | |
| WO2025103391A1 (zh) | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 | |
| US20250388897A1 (en) | Nucleic acid compounds |